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To analyze the glycosylation of anti-𝛽2GP1, we investigated purified IgG from healthy children, patients with APS, and
asymptomatic adult carriers of antiphospholipid antibodies. We observed that in the sera of healthy children and of patients with
APS, IgG3 and IgG2 were predominant, respectively. The potentially protective anti-𝛽2GP1-IgM was lower in the sera of healthy
children. Although anti-𝛽2GP1-associated C1q did not differ between children and patients with antiphospholipid syndrome, the
associated C3c was significantly higher in the sera of healthy children. This indicates a more efficient clearance of anti-𝛽2GP1
immune complexes in the healthy children. This clearance is not accompanied by inflammation or coagulatory events. It is likely
that the most important pathogenic factor of the anti-𝛽2GP1-IgG is related to the different glycosylation observed in healthy and
diseased individuals. We detected a significantly higher sialylation of anti-𝛽2GP1-IgG isolated from the sera of healthy children
and asymptomatic adults when compared with that of patients with clinically apparent antiphospholipid syndrome. Low sialylated
IgG reportedly ameliorates inflammation and inflammation promotes hyposialylation. Thus, both reactions create a vicious circle
that precipitates the pathology of the antiphospholipid syndrome including thrombus-formation. We conclude that the increased
sialylation of anti-𝛽2GP1-IgG of sera of healthy individuals limits their pathogenicity.
1. Introduction
Theantiphospholipid syndrome (APS) is an autoimmune dis-
ease affecting the coagulation system. Its diagnosis requires
at least one clinical criterion and one serological criterion as
defined during conferences held in 1998 and in 2006 [1, 2].
The serological criteria include the detection of so-called
antiphospholipid antibodies (aPL) which comprise the lupus
anticoagulant (LA), anticardiolipin autoantibodies (aCL),
and anti-𝛽2-glycoprotein 1 autoantibodies (anti-𝛽2GP1) [1].
Thrombosis as one major symptom in APS is mainly
associated with anti-𝛽2GP1 [3]. 𝛽2GP1 is a plasma protein
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composed of five domains [4] and it is known to be an
inhibitor of the contact activation of the intrinsic coagulation
pathway [5]. Additionally, aPL can cause a prothrombotic
state in individuals by activating platelets and endothelial
cells resulting in a higher expression of tissue factor or in the
upregulation of proinflammatory cytokines and cell adhesion
molecules [6, 7].
Patients with APS can be classified into two groups
depending on the occurrence of further diseases: (I) patients
merely suffering from APS (primary antiphospholipid syn-
drome; PAPS) and (II) those with an underlying systemic
lupus erythematodes (SLE). The latter condition is referred
to as secondary antiphospholipid syndrome (SAPS) [8].
Up to now, a variety of hypotheses about possible triggers
for the induction of anti-𝛽2GP1 have been proposed. Pub-
lished studies suggest that their production can be provoked
during infectious diseases like parvovirus B19, HIV, CMV,
or HCV [3, 9–11]. Certain molecular structures of these
infectious agents may resemble structures of 𝛽2GP1 and thus
cause the induction of cross-reacting antibodies [7, 12–16].
Another one claims that nutritional exposure to 𝛽2GP1 could
also trigger the production of transient and harmless anti-
𝛽2GP1 in children [4, 17–19].
Interestingly, anti-𝛽2GP1 can be detected in a quite large
proportion of the healthy population who do neither suffer
from APS nor another autoimmune disease [3, 18, 20].
As complication-free periods of patients with APS occur
although the aPL are persistently detectable in their circula-
tion [15], it seems to be likely that the mere presence of these
antibodies is not sufficient for the development of clinical
active APS complications.
For this reason, a two-hit hypothesis has been proposed
to provide a putative explanation for this observation. (I)
the production of anti-𝛽2GP1 represents an initial hit that
increases the risk for thrombotic events and (II) infectious
agents can then serve as the second hit provoking the typical
manifestations of APS by activating toll-like receptors or
complement [9, 15, 21, 22]. This two-hit hypothesis surely
provides a good first model for the etiopathogenesis of APS.
Yet it is not completely satisfying and does not explain why
some people harbouring aPL remain healthy. Some study
results indicate that this could be grounded in structural
differences of anti-𝛽2GP1 found in patients with APS and
healthy children [4, 23].
Comparing obviously harmless aPL from healthy chil-
dren with putatively pathogenic aPL from adults with APS,
we suggested a difference in the epitope specificity as differ-
entiating factor. Anti-𝛽2GP1 from the sera of the children
specifically bound to the domain IV/V of 𝛽2GP1, whereas
anti-𝛽2GP1 from adults with APS preferentially targeted
domain I [24]. These results were consistent with those
described in other studies [19, 25]. Besides distinct epitope
binding specificities, a different composition of the spectrum
of the anti-𝛽2GP1 IgG subclasses between patients with APS
and healthy carriers of this antibody has also been described
[19, 23, 26, 27].
The differences in glycosylation of antibodies which are
accompanied by crucial modifications of their effector func-
tions [28] provide another promising approach in performing
structural analyses of anti-𝛽2GP1. IgG molecules possess a
biantennary oligosaccharide attached to the asparagine at
position 297 of the Fc portion (Asn-297). Various glycoforms
containing distinct sugar moieties have been described [28,
29]. Interestingly, it has been observed that IgG molecules
whose glycans terminate with sialic acid residues show
a decreased affinity to activating Fc𝛾-receptors (Fc𝛾Rs)
while simultaneously provoking an upregulation of the
inhibitory Fc𝛾RIIB [29–31]. These effects lead to a rather
anti-inflammatory activity andmight consequently be able to
prevent potentially harmful immune responses.
In particular in children, aPL can readily be detected
although they do not show any clinical signs of APS. In a
study carried out by Avcˇin et al., the prevalence of anti-
𝛽2GP1 in 61 healthy children was 6.6% [18]. Based on this
observation we intended to find out why these circulating
autoantibodies do not cause harm in their hosts. We deter-
mined the IgG-subclass distribution in the samples from
healthy children and patients with APS and examined the
binding of the complement factors C1q and C3c to anti-
𝛽2GP1 immune complexes, since an important involvement
of the complement system in the pathogenesis of APS has
been reported [21, 22, 32]. Finally we analysed the sialylation
status of anti-𝛽2GP1-IgG isolated from healthy children,
asymptomatic adult carriers, and patients with APS.
Our results revealed that, compared to adults with APS,
the healthy children showed a higher content of IgG3 at the
cost of IgG2 of the anti-𝛽2GP1. Furthermore, anti-𝛽2GP1-IgG
of healthy children showed a higher sialylation and displayed
more bound C3c. Hyposialylated IgG and inflammation
mutually influence the pathogenicity of the antiphospholipid
autoantibodies and form a vicious pathogenic circle.
2. Materials and Methods
2.1. Patients. For the investigation of anti-𝛽2GP1-IgG, its
subclasses, C1q- and C3c-binding and anti-𝛽2GP1-IgM, we
studied sera of 46 adult patients (24 patientswith PAPS and 22
with SAPS) and 16 healthy children harbouring anti-𝛽2GP1
without any clinical manifestations associated with APS from
our partner hospital in Brescia, Italy. As a control group,
we examined sera of 17 age and sex matched adult normal
healthy donors (NHD) without aPL. Inclusion criteria for the
children were the presence of anti-𝛽2GP1-IgG, no infectious
diseases in the course of three months before blood taking,
and no chronic pathology. Additionally, it was excluded that
their parents suffered from any autoimmune disease. At the
time of blood taking, the mean age of the children was about
9 months (median age: 8.5 months; range: 3 months and 5
days–19 months and 10 days).
Since sugar residues attached to molecules can be dam-
aged by repeated thawing and freezing, we received new
sera from our partner hospital in Brescia, Italy, to analyse
the sialylation of anti-𝛽2GP1-IgG. We obtained sera from 12
patients with PAPS and 10 patients with SAPS, 15 patients
with SLE and aPL but without clinical evidence of APS
and sera from 6 asymptomatic carriers of aPL. Furthermore,
we obtained sera from 16 healthy children showing no
symptoms of APS although harbouring anti-𝛽2GP1-IgG in
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Table 1: Antibodies employed for each ELISA.
ELISA Detection-antibody Dilution
Anti-𝛽2GP1-IgG HRP-conjugated rabbit F(ab󸀠) 2 anti-human-IgG∗ 1 : 20.000
Anti-𝛽2GP1-IgG subclasses HRP-conjugated mouse anti-human IgG1, 2, 3 and 4 (Clones HP6001,HP6002, HP6050 & HP6025)∗ 1 : 20.000
Anti-𝛽2GP1-IgM HRP-conjugated goat anti-human-IgM∗ 1 : 20.000
Anti-𝛽2GP1-bound C3c HRP-conjugated sheep anti-C3c∗∗ 1 : 500
Anti-𝛽2GP1-bound C1q HRP-conjugated sheep anti-C1q∗∗ 1 : 500
∗: purchased from Southern Biotech, Birmingham, Alabama, USA.
∗∗: purchased from Abcam, Cambridge, United Kingdom.
HRP = horseradish peroxidase.
their circulation (mean age: 9.5 months; median age: 10
months; range: 3 months and 5 days–19 months and 10 days).
2.2. Blood Drawing. Heparinised venous blood was drawn
by venipuncture and processed within two hours. Serum was
obtained by centrifugation at 1000 g for 15 minutes of clotted
blood, then aliquoted, frozen, and stored at −20∘C until use
for investigation.
Informed consent was obtained from all blood donors
and the children’s parents, respectively, and the study was
approved by the ethics committees of the University Hospital
Erlangen and the Spedali Civili Brescia.
2.3. Isolation of 𝛽2GP1. For 𝛽2GP1-isolation from diluted
sera of normal healthy donors (in 0.15MNaCl), percloric acid
was slowly added until the mixture got a creamy aspect. After
centrifugation at 10.000 g, the supernatant was neutralized
with NaOH and dialyzed against a buffer of 0.02M Tris and
0.03MNaCl, pH8.Then itwas given into columns containing
HiTrap heparin and contaminants of the supernatant were
eluted by the addition of 0.02M Tris and 0.15M NaCl, pH 8.
In order to elute semipurified 𝛽2GP1, a buffer of 0.02M Tris,
and 0.35MNaCl, pH 8 was injected into the columns and the
fractions have been pooled and dialyzed against a solution
containing 0.05M acetate buffer, 0.05M NaCl, pH 4.8. This
material was filtrated with 0.2𝜇membranes and injected into
resin columns equilibrated with 0.05M acetate buffer, 0.05M
NaCl, pH 4.8. After washing with 0.05M acetate buffer,
0.65M NaCl, pH 5.2, the fractions were pooled and dialyzed
against PBS, pH 7.2. To verify the purity of isolated 𝛽2GP1,
a sodium dodecyl sulfate polyacrylamide gel electrophoresis
(SDS-PAGE) has been performed.
2.4. Purification of Anti-𝛽2GP1-IgG. For the analysis of the
sialylation of anti-𝛽2GP1-IgG, we isolated IgG antibodies
from the sera to exclude possible interactions of the detection
lectin with anti-𝛽2GP1-IgM in the samples. Purification of
anti-𝛽2GP1-IgG was performed as follows: 20𝜇L of serum
was added to 50𝜇L magnetic Dynabeads Protein G (Novex
by life technologies, Carlsbad, CA, USA) and incubated for
45 minutes at room temperature. After washing with 1x TBS,
glycin-HCl, pH 2.6, was added for 5 minutes to elute the anti-
𝛽2GP1-IgG. The supernatant, now containing the IgG anti-
bodies, was neutralized with Tris-HCl, pH 8.8, and all sam-
ples were centrifuged using 100K Amicon Ultra-centrifugal
filter devices (Millipore, Tullagreen, Ireland) to transfer them
into 300 𝜇L TBS-buffer.
2.5. Serum ELISAs: Anti-𝛽2GP1-IgG, -IgG1, -IgG2, -IgG3,
-IgG4, and -IgM and C3c and C1q Bound to Anti-𝛽2GP1.
To quantify the amount of anti-𝛽2GP1-IgG and its four
subclasses, of C3c and C1q associated with anti-𝛽2GP1 and
of anti-𝛽2GP1-IgM in the sera of patients with PAPS and
SAPS, NHD, and healthy children, we performed enzyme-
linked immunosorbent assays (ELISA). In detail, the surface
of F 96NUNCmaxisorpmicrotiter plates (Thermo Scientific,
Roskilde, Denmark) was coated with 50 𝜇L of a 2 𝜇g/mL
solution of 𝛽2GP1 in coating buffer (100mM Na
2
CO
3
,
100mM NaHCO
3
, pH 9.6) at 4∘C overnight. After washing
the plates three times with washing buffer (WB; 0.05% Tween
20, 0.1mM CaCl
2
, 0.1mM MgCl
2
in TBS buffer (150mM
NaCl, 50mM TrisHCl, pH = 7.4)), the wells of the coated
plates were blocked with 100 𝜇L/well of a 2% BSA solution
for two hours at 37∘C. After three further washing steps with
WB, 50 𝜇L/well of diluted serum (1 : 200 in WB) was added
and the plates were incubated at 37∘C for two further hours.
Then, the plates were washed three times with WB again.
Development of the plates based on an enzymatic
reaction of horseradish peroxidase (HRP) with TMB as
chromogenic substrate. Therefore, the appropriate HRP-
conjugated detection-antibody was added as a next step
(Table 1). After incubation at 37∘C for another hour and
three washing steps with WB, the plates were devel-
oped by the addition of 50𝜇L/well of freshly prepared
TMB-solution (1mL of 0.01 g 3,3󸀠,5,5󸀠-tetramethylbenzidine
(Sigma-Aldrich, Steinheim, Germany) dissolved in 10mL
dimethyl sulfoxide, mixed with 9mL of 0.1M Na
2
HPO
4
,
0.05M citric acid, pH 4.5–5.5, and 2𝜇L of H
2
O
2
). The
reaction was stopped by adding 50𝜇L/well of 25% sulfuric
acid (H
2
SO
4
). Finally, optical density (OD) was measured
at 450 nm and 650 nm as correction factor using an infinite
F200 pro ELISA-reader (Tecan).
After subtraction of the corresponding blank values of the
plates, experimental values were expressed as optical density
or as mean optical density of each serum when ELISA tests
were performed in monoplicates or duplicates, respectively.
2.6. IgG-ELISA: SNA. In order to examine the sialylation
of anti-𝛽2GP1-IgG, we slightly modified the previously
described ELISA protocol. Before coating, the 𝛽2GP1 antigen
was treated with 1% of periodic acid (PIA, Sigma-Aldrich,
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Table 2: Detection reagents for lectin ELISA.
SNA-ELISA
Primary detection
reagent
Biotinylated SNA-lectin
(Galab Technologies, Geesthacht, Germany)
Secondary
detection reagent
HRP-conjugated streptavidin
(Jackson ImmunoResearch laboratories,
Newmarket, Suffolk, United Kingdom)
Dilution 1 : 10.000
SNA = Sambucus nigra agglutinin; HRP = horseradish peroxidase.
Steinheim, Germany) for 48 hours at 43∘C to remove its
sugar residues to exclude unspecific binding of Sambucus
nigra lectin (SNA) to naive 𝛽2GP1. After that, we centrifuged
the 𝛽2GP1-solution with 10K Amicon Ultra-centrifugal fil-
ter devices (Millipore, Tullagreen, Ireland) to transfer the
treated 𝛽2GP1 into coating buffer (100mMNa
2
CO
3
, 100mM
NaHCO
3
, pH 9.6).
Then, the plates were coated with 50 𝜇L/well of a 2𝜇g/mL
solution of the PIA-treated 𝛽2GP1 at 4∘C overnight and
subsequently blocked for two hours at 37∘C with 100 𝜇L/well
of PIA-treated (0.5%) 3% gelatine (Sigma-Aldrich, Steinheim,
Germany) in TBST buffer with 1mM CaCl
2,
and 1mM
MgCl
2
. The subsequent steps were performed as described
in the previous ELISA protocol with two exceptions. Instead
of serum, we added 50 𝜇L/well of purified IgG-samples to
exclude possible binding of SNA to anti-𝛽2GP1-IgM. And the
development of the plate required the addition of a second
detection reagent (Table 2), which was incubated for one
hour at room temperature and demanded three preliminary
washing steps. We calculated the SNA/anti-𝛽2GP1-IgG ratio
from the OD values we obtained in the SNA ELISA and a
simultaneously conducted anti-𝛽2GP1-IgG ELISA.
2.7. Statistical Analysis. Differences between the cohorts were
assessed using the one-way analysis of variance (ANOVA)
test. In the case of multiple testing, the significance values
were adjusted by the Newman-Keuls posttest correction.
3. Results
3.1. Analysis of Anti-𝛽2GP1-IgG. Wemeasured the OD values
of total anti-𝛽2GP1-IgG in the sera of 24 patients with PAPS
and 22 patients with SLE/APS, 16 healthy children, and
17NHD as controls. As shown in Figure 1, the lowest IgG
values were to be observed in the cohort of healthy donors
(308mOD), whereas the values of the healthy children
(970mOD) even exceeded that of the patients with APS
(PAPS: 686mOD, 𝑝 = 0.010; SLE/APS: 546mOD, 𝑝 <
0.001). All differences between NHD and the other cohorts
as well as between the children and the other cohorts were
significant. Patients with PAPS and SLE/APS did not differ
significantly.
We calculated the 97.5% quantile of the anti-𝛽2GP1-IgG
OD values obtained from the NHD cohort and set this value
as cut-off (738mOD). Sera exceeding this value were consid-
ered seropositive for anti-𝛽2GP1-IgG. Applying this cut-off
value, we obtained 31 seropositive samples (12/24 PAPS, 6/22
SAPS, 13/16 healthy children), which were further analysed in
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Figure 1: Total anti-𝛽2GP1 IgG in the sera of NHD, PAPS,
SLE/APS, and healthy children and the corresponding 𝑝 values.
NHD showed significantly lower mOD values than all other cohorts
whereas healthy children represented the highest mOD values.
Short horizontal lines: mean mOD values of all samples of the
cohort. Long broken line: 97.5% quantile of NHD (=738mOD);
NHD = normal healthy donor; PAPS = primary antiphospholipid
syndrome; SLE/APS = antiphospholipid syndrome with systemic
lupus erythematosus; OD = optical density.
our study (Supplementary Figure 1, in Supplementary Mate-
rial available online at http://dx.doi.org/10.1155/2015/638129).
3.2. Analysis of the IgG-Subclasses of Anti-𝛽2GP1. Analysing
the absolute OD values of the anti-𝛽2GP1-IgG subclasses,
we observed that the children showed significantly higher
levels of the anti-𝛽2GP1-IgG1 (69mOD) and -IgG3 subclasses
(212mOD) compared to NHD, PAPS, and SAPS (Figures
2(a) and 2(c); Table 3(a)). The differences between healthy
children and NHD regarding these two subclasses showed
a higher level of significance than the comparison between
healthy children and patients with APS. However, healthy
children did not show significant differences for anti-𝛽2GP1-
IgG2 and -IgG4 when compared to NHD, PAPS, and SAPS
(Figures 2(b) and 2(d); Table 3(b)).
Patients with APS (PAPS and SAPS) showed significantly
higherODvalues for anti-𝛽2GP1-IgG1, -IgG2, and -IgG3 than
NHD (Figures 2(a), 2(b), and 2(c); Table 3(b)). As in the
anti-𝛽2GP1-IgG ELISA, we observed no significant difference
between the patients with PAPS and SAPS.
To summarize, patients with APS showed higher OD
values than NHD in IgG1, IgG2, and IgG3. IgG4 did not
show any significant difference.The children, in turn, had the
highest OD values of the IgG1 and IgG3 subclasses.
These results were consistent with the analysis of the
number of seropositive samples, as shown in Table 4. To
determine seropositivity, we calculated the mean OD and the
standard deviation (SD) of the NHD group for the different
IgG subclasses. IgG values exceeding the NHD’s mean OD
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Figure 2:mODvalues of anti-𝛽2GP1-IgG1 (a), anti-𝛽2GP1-IgG2 (b), anti-𝛽2GP1-IgG3 (c), and anti-𝛽2GP1-IgG4 (d) inNHD, PAPS, SLE/APS,
and children.The horizontal lines represent the cut-off for seropositivity of the corresponding anti-𝛽2GP IgG-subclass (>meanmOD
[NHD] +
2 × SD
[NHD]); NHD = normal healthy donor; PAPS = primary antiphospholipid syndrome; SLE/APS = antiphospholipid syndrome with
systemic lupus erythematosus; OD = optical density. Median OD values of the anti-𝛽2GP1-IgG subclasses in the study cohorts (e). Regarding
the anti-𝛽2GP1-IgG subclass-distribution within the cohorts, children showed a significantly higher contribution of IgG3 than IgG1 and
IgG2. Patients with antiphospholipid syndrome (APS) showed a higher content of anti-𝛽2GP1-IgG2 than -IgG1 and -IgG3. NHD showed a
higher contribution of anti-𝛽2GP1-IgG2 than -IgG1, -IgG3, and -IgG4.The columns represent the median OD values of IgG1, IgG2, IgG3, and
IgG4 in the cohorts. OD = optical density; NHD = normal healthy donor. Percentage distribution of anti-𝛽2GP1-IgG subclasses in children
and patients with APS (f). Children harbour significantly less anti-𝛽2GP1-IgG2 than patients with APS but more anti-𝛽2GP1-IgG3. APS =
antiphospholipid syndrome.
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Figure 3: OD values of C3c (a) bound to anti-𝛽2GP1 and OD values of anti-𝛽2GP1-IgM (b) in sera of patients with APS and healthy children.
Anti-𝛽2GP1 of healthy children displayed significantly more bound C3c than that of patients with APS (𝑝 = 0.00007). This suggests a more
efficient clearance of 𝛽2GP1-immune complexes in the healthy children. Anti-𝛽2GP1-IgM OD values of patients with APS were significantly
higher than those of healthy children. Horizontal lines represent the median OD value of the cohort. APS = antiphospholipid syndrome; OD
= optical density.
Table 3: (a) OD values of the anti-𝛽2GP1-IgG subclasses in the
investigated cohorts. (b) Comparison (𝑝 values) of the OD values
of the anti-𝛽2GP1-IgG subclasses.
(a)
IgG1 [mOD] IgG2 [mOD] IgG3 [mOD] IgG4 [mOD]
NHD 24 64 27 67
Children 69 77 212 210
PAPS 30 85 45 72
SAPS 28 74 55 173
APS 29 81 48 106
(b)
IgG1 IgG2 IgG3 IgG4
Children versus NHD <0.0001 n.s. <0.0001 n.s.
Children versus PAPS <0.0001. n.s. <0.001 n.s.
Children versus SAPS <0.001 n.s. <0.001 n.s.
APS versus NHD n.s. n.s. n.s. n.s.
PAPS versus SAPS n.s. n.s. n.s. n.s.
OD = optical density 450 nm; PAPS = primary antiphospholipid syndrome;
SAPS = secondary antiphospholipid syndrome; APS = PAPS and SAPS;
NHD = normal healthy donors; n.s. = not significant.
plus two times the SD of the considered subclass were defined
as seropositive (Supplementary Figure 1). Applying this cut-
off, we observed that the healthy children had high levels of
the IgG1 and IgG3 subclasses, with 13 (100%) and 8 (62%)
seropositive samples, respectively. In contrast, only 7 (39%)
and 0 (0%) sera of patients with APS were seropositive for
IgG1 and IgG3, respectively. APS showed seropositivity of
anti-𝛽2GP1-IgG2 in 7 cases (39%), whereas the cohort of
healthy children contained just 2 seropositive sera (15%). Just
few samples were seropositive for anti-𝛽2GP1-IgG4 in each
cohort, representing a range from 8% (PAPS) to 17% (SAPS).
To determine the subclass distributionwithin the cohorts,
we calculated the contribution of themeanOD values of each
individual subclass to the sum.
As shown in Figures 2(e) and 2(f), we saw that for the
healthy children IgG3 was the most abundant subclass with
a contribution of 40% (IgG3 > IgG1 (𝑝 < 0.001) and IgG3 >
IgG2 (𝑝 < 0.01)). In contrast, IgG2 dominated the subclass
profile for NHD (46%; IgG2 > IgG1, IgG2 > IgG3, and IgG2 >
IgG4 (𝑝 < 0.0001)) and patients with APS (38%; IgG2 > IgG1
(𝑝 < 0.0001), IgG2 > IgG3 (𝑝 = 0.001)). The contribution
of IgG1 ranged from 12% (SAPS) to 17% (NHD) and that
of IgG4 from 21% (PAPS) to 35% (SAPS). Comparing the
contribution of the individual subclasses between the study
cohorts, we observed that children showed significantly less
IgG2 than patients with APS and NHD (𝑝 < 0.001; 𝑝 <
0.0001) and a higher IgG3 content than NHD and patients
with APS (𝑝 < 0.0001; 𝑝 < 0.001). No significant difference
between the cohorts was to be seen for the contributions of
IgG1 and IgG4.
3.3. Analysis of IgM, C1q, and C3c Associated to Anti-𝛽2GP1-
IgG. Next we analysed potential 𝛽2GP1-binding proteins in
the sera of healthy children and adults with APS. The signals
for C1q were low and did not differ significantly between the
cohorts.
However, the ELISAs detecting C3c bound to anti-𝛽2GP1
and anti-𝛽2GP1-IgM showed highly significant differences
between healthy children and adults with APS.Whereas C3c-
anti-𝛽2GP1 adducts were increased in healthy children (𝑝 <
0.0001; Figure 3(a)), anti-𝛽2GP1-IgM was decreased (𝑝 <
0.001; Figure 3(b)).
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Table 4: Number (frequency) of seropositive samples of the anti-𝛽2GP1-IgG subclasses.
Number of seropositive samples (>mOD[NHD] + 2 × SD[NHD])
IgG1
(>2,9mOD)
IgG2
(>7,9mOD)
IgG3
(>8,5mOD)
IgG4
(>31,9mOD)
NHD (𝑛 = 17) 0 (0%) 0 (0%) 1 (6%) 1 (6%)
Children (𝑛 = 13) 13 (100%) 2 (15%) 8 (62%) 2 (15%)
PAPS (𝑛 = 12) 6 (50%) 5 (42%) 0 (0%) 1 (8%)
SAPS (𝑛 = 6) 1 (17%) 2 (33%) 0 (0%) 1 (17%)
APS (𝑛 = 18) 7 (39%) 7 (39%) 0 (0%) 2 (11%)
OD = optical density 450 nm; PAPS = primary antiphospholipid syndrome; SAPS = secondary antiphospholipid syndrome; APS = PAPS and SAPS; NHD =
normal healthy donors.The cut-off for seropositivity was calculated from the mean OD of the corresponding anti-𝛽2GP1-IgG subclass of the NHD cohort and
its standard deviation (SD) according to the formula: mean OD[NHD] + 2 × SD[NHD]. The respective cut-off OD values are indicated in parentheses below the
anti-𝛽2GP1-IgG subclasses.
Table 5: Cohorts studied with the lectin ELISA.
Cohort Abbreviation Number of samples
Patients with primary APS PAPS 12
Patients with APS and SLE as underlying disease SAPS 10
Patients with SLE without symptoms of APS harbouring circulating aPL SLE + aPL 15
Asymptomatic carriers of aPL aaPL 6
Healthy children with circulating anti-𝛽2GP1 — 16
APS = antiphospholipid syndrome; aPL = antiphospholipid antibodies; SLE = systemic lupus erythematosus.
3.4. Analysis of the Sialylation of Anti-𝛽2GP1. We analysed
the glycosylation of anti-𝛽2GP1-IgG, focusing on its sialy-
lation since highly sialylated Fc-parts of IgG are known to
cause rather anti-inflammatory responses [30]. Wemeasured
the binding of the sialic acid specific lectin SNA to the anti-
𝛽2GP1-IgG. As shown in Table 5, we employed five cohorts of
individuals: 12 patientswith PAPS, 10 patientswith SAPS (SLE
as primary disease), 15 patients with SLE who did not show
clinical sign of APS but with aPL in their sera (SLE + aPL),
6 asymptomatic adult carriers of aPL (aaPL), and 16 healthy
children, harbouring aPL.
Analysing the SNA/IgG-ratios (Figure 4), we identified
the highest sialylation level in the sera of the healthy children.
The significances were rather high and decreased from PAPS
(𝑝 < 0.0001) to SAPS (𝑝 < 0.0001), to SLE + aPL (𝑝 <
0.0001), and to aaPL (𝑝 < 0.001).
4. Discussion
We analysed two distinct sets of sera. One was used to
investigate anti-𝛽2GP1-IgG, its subclasses, and its associated
proteins C1q and C3c. For the analysis of the sialylation of
anti-𝛽2GP1-IgG, we had to collect fresh sera from patients
with APS and the healthy children since the stability of the
antibody-glycosylation is unknown. In order to avoid its
possible decay by processes like enzymatic degradation, this
period has been kept as short as possible and was followed by
immediate investigation of the glycosylation.
The antiphospholipid syndrome is characterized by clin-
ical manifestations such as arterial and venous thrombosis
or pregnancy-related complications and the detection of spe-
cific autoantibodies (lupus anticoagulant, anti-𝛽2GP1- and
anticardiolipin-autoantibodies) [1]. In particular anti-𝛽2GP1s
are considered responsible for provoking the pathological
complications [3].We firstmeasured the total amount of anti-
𝛽2GP1-IgG in the sera of 16 healthy children without clinical
manifestations of APS and 46 adult patients with APS to
identify individual cohorts seropositive for anti-𝛽2GP1. 17
adult normal healthy donors served as negative control.
The samples of the patientswithAPS showedhigher levels
of anti-𝛽2GP1-IgG than those of NHD. We also observed
a higher concentration of anti-𝛽2GP1-IgG in the sera of
healthy children compared to NHD. This is due to the fact
that the detection of these antibodies has been the inclusion
criterion for the healthy children examined in this study.
Interestingly, the children showed even higher OD values for
the putatively pathogenic anti-𝛽2GP1-IgG than the patients
with APS. This finding was surprising since the children
were clinically healthy and did not show any signs of APS
such as thrombosis or thrombocytopenia, complications in
which the existence of aPL, especially anti-𝛽2GP1, is made
responsible for [7, 33].
High levels of circulating aPL in 61 healthy children, when
compared to healthy adults, have already been described by
Avcˇin and colleagues [18]. The anti-𝛽2GP1-IgG was report-
edly higher in preschool children with a mean age of 5
years than in adolescents with a mean age of 13.5 years
[18]. The strongly elevated circulating anti-𝛽2GP1-IgG in our
cohort of healthy children may be explained by the fact that
they had an even lower age (mean age was nine months).
One possible explanation for this result is the induction
of anti-𝛽2GP1 by viral and bacterial infections [10, 11] or
nutritional exposure to 𝛽2GP1 [17]. As the immune system
in children is still to evolve, they are more susceptible to
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Figure 4: SNA/anti-𝛽2GP1-IgG ratio in PAPS, SAPS, SLE + aPL,
aaPL, and children. Healthy children show a significantly higher
SNA/anti-𝛽2GP1-IgG ratio than PAPS, SAPS, SLE + aPL, and aaPL
(∗∗𝑝 < 0.0001; ∗∗∗𝑝 < 0.00001). This suggests higher sialylation of
the oligosaccharides attached to Fc fragments of the children’s anti-
𝛽2GP1.No significant differenceswere foundbetween the remaining
cohorts. Horizontal lines indicate the mean SNA/IgG ratio of the
cohort. SNA = Sambucus nigra agglutinin; APS = antiphospholipid
syndrome; PAPS = patients with primary APS; SAPS = patients with
APS and SLE as underlying disease; SLE + aaPL = patients with
SLE without symptoms of APS harbouring circulating aPL; aaPL =
asymptomatic carriers of aPL; aPL = antiphospholipid antibodies;
SLE = systemic lupus erythematosus.
infections than adults and their immune system has to cope
with a plethora of viral and bacterial pathogens for the first
time in their life. This scenario is prone to result in the
stimulation of autoantibody-production. Molecular mimicry
of certain pathogens can lead to the production of antibodies
which then cross-react with 𝛽2GP1 [7, 12–15]. When infants
diversify their dietary habits and start to consume products
like milk and meat, they can get into contact with nutritional
𝛽2GP1 [19]. This is a further condition capable triggering
the production of anti-𝛽2GP1. Exposure to pathogen-derived
and dietary 𝛽2GP1 could explain the high level of circulating
anti-𝛽2GP1-IgG in healthy children.This low affine reactivity
is consecutively lost during the maturation of the immune
system and replaced by the emergence in adults of high affine
antibodies that more specifically recognize pathogens. Apart
from possible origins of these autoantibodies, it is obvious
that they do not provoke any of the hallmark symptoms of
APS. In contrast to their adult counterparts, anti-𝛽2GP1-IgGs
circulating in the plasma of healthy children are obviously
not pathogenic. So it seems decent to hypothesize that
anti-𝛽2GP1 autoantibodies in healthy children biochemically
differ from those in adults.
To test this hypothesis, we examined the anti-𝛽2GP1-
IgG subclass distribution in the seropositive sera of the anti-
𝛽2GP1-IgG ELISA. The healthy children showed higher OD
values for the IgG1- and IgG3-subclasses than patients with
APS and NHD. This was consistent with the number of
seropositive samples. In the anti-𝛽2GP1-IgG1-subclass, every
tested serum of the healthy children surpassed the threshold
set for seropositivity (>mean OD
[NHD] + 2 × SD[NHD]) and
8 samples (62%) did so in the IgG3-subclass. In the sera
of patients with APS, just 7 (39%) and no samples were
seropositive for IgG1 or IgG3. In the sera of patients with APS
compared to NHD, we observed higher OD levels of anti-
𝛽2GP1 in all subclasses, except for IgG4.This result is consis-
tent with the findings of Guerin et al. who reported elevated
levels in all anti-𝛽2GP1-IgG subclasses, even including IgG4,
in patients with APS compared to a control group of healthy
adults [23].
It might be that the elevated absolute OD values of the
anti-𝛽2GP1-IgG subclasses are the logical consequence of
the generally higher level of anti-𝛽2GP1-IgG in the patients
with APS and healthy children who were selected for further
testing. Therefore, we also analysed the subclass distribution
of this antibody. We first analysed the anti-𝛽2GP1-IgG sub-
class distribution within the individual cohorts and observed
that in the healthy children the IgG3 antibody was most
abundant with a contribution of 40% to the total reactivity.
This is consistent with the finding that all sera of the healthy
children were seropositive in this subclass and that their
anti-𝛽2GP1-IgG3 OD values were the highest of all cohorts.
This indicates a predominance of this subclass in the healthy
children. The remaining anti-𝛽2GP1-IgG subclasses in the
sera of the children ranged from 15% (IgG1) over 20% (IgG2)
to 25% (IgG4) but the differences between their proportions
were not statistically significant. In contrast, in the sera of
the patients with APS, the anti-𝛽2GP1-IgG2 subclass had the
highest contribution with 38%.
The finding of an elevated proportion of the IgG2 subclass
in the patients with APS confirms former published data
which also describe a skewing towards anti-𝛽2GP1-IgG2 in
APS [19, 23, 26, 27]. The authors detected an even higher
contribution of anti-𝛽2GP1-IgG2 (70.2% [26] and 87% [27],
resp.). In contrast to our results, the IgG1 subclass was
more prominent in the published studies described above.
Importantly, in the cohort of the healthy infants IgG2 was
relatively low.Therefore onemay argue that anti-𝛽2GP1-IgG2
is not just a marker of the disease but is also involved in
the pathogenic action of the aPL autoantibodies. When we
compared the anti-𝛽2GP1-IgG subclass distribution between
the three cohorts, we noticed a significant difference in the
distribution concerning the children on one hand and NHD
and patients with APS on the other. Healthy children showed
a higher proportion of anti-𝛽2GP1-IgG3 and a lower one of
anti-𝛽2GP1-IgG2. In NHD and patients with APS, it was the
other way round. IgG1 and IgG4 did not significantly differ
between healthy children and patients with APS orNHD.The
predominance of anti-𝛽2GP1-IgG3 in the healthy children is
a hint to an immune response elicited by a proteinaceous
antigen [26, 27, 34]. This supports the hypothesis that
the harmless anti-𝛽2GP1 in children are infection-induced
with pathogen-derived proteins serving as trigger for their
production. However, it is still elusive if the IgG3-dominated
anti-𝛽2GP1 response, found in the sera of healthy children,
contributes to its low pathogenic potential. Alternatively,
it can just be ascribed to the proceeding evolution of the
infant’s immune system typically associated with an elevated
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proportion of IgG3 antibodies [34, 35]. During childhood,
the proportion of IgG3 continuously decreases to adult ranges
usually reached at the age of 10–12 years. However, the above
average elevated proportion of the anti-𝛽2GP1-IgG3 (40%) in
the sera of the healthy childrenmay thus not just be due to the
infant immune system. In particular when bearing in mind
that normal adult levels of the IgG3 subclass are just around
6% [34, 36].
IgG3 is the IgG-subclass exerting the most effective
activation of the complement cascade through the classical
pathway [34]. Since complement activation is associated with
the pathogenesis of APS [21, 32, 37], the high proportion
of complement-activating anti-𝛽2GP1-IgG3 in the children
seems to contradict a possible protective effect against APS of
these kinds of antibodies. However, the role of complement in
the etiopathogenesis of autoimmune diseases is manifold as
the complement components C1q, C2, and C4 contribute to
the clearance of postapoptotic, secondary necrotic cells and
their deficiency is, therefore, a risk factor for autoimmunity
and autoinflammation [38]. In a similar manner, studies
in mouse in vivo models of various autoimmune diseases
demonstrated that IgG mediated tissue inflammation was
blocked in mice deficient in activating Fc𝛾Rs, although the
complement component C3 was still abundantly deposited
in the tissue [39–41]. Thus, the contribution of complement
deposits in tissue with respect to tissue inflammation remains
to be established.
To obtain new insights into the involvement of the
complement system in the pathogenesis of APS, we analysed
the C1q- and C3c-binding to anti-𝛽2GP1. We observed that
anti-𝛽2GP1 in the sera of the healthy children and in patients
with APS similarly bound C1q, the first molecule of the
classical pathway of complement activation [42]. Performing
anti-𝛽2GP1-IgM-ELISAs, we detected significantly higher
IgM values in the patients with APS. One would expect
a higher C1q-binding of the IgM positive sera, since this
immunoglobulin binds and activates C1q more strongly than
IgG. However, the children mainly harbour IgG3 autoanti-
bodies, the most potent subclass for the activation of the
classical complement pathway [34].This may compensate for
the lower IgM level in their sera and thus be responsible
for the similar C1q-binding of both cohorts. This suggests
that preconditions for complement activation via the classical
pathway are comparable in both cohorts. We conclude that
classical complement activation has a minor impact on the
differential pathogenesis of aPL in healthy children and
patients with APS.
What then is the culprit that induces their pathogenic
potential?
Nextwe quantified the contribution ofC3c to the immune
complexes bound to 𝛽2GP1. C3c is a domain in the C3b
molecule and one of its cleavage products created after
cleavage by factor I of C3b [42, 43]. C3c not just represents
a marker of complement activation but also serves as an
opsonin, improving the clearance of bound targets. We
observed significantly more C3c bound to anti-𝛽2GP1 in
the sera of the healthy children than in those of patients
with APS. This reflects a better opsonization by C3c of
the potentially harmful anti-𝛽2GP1 immune complexes,
anti-𝛽2GP1-opsonized cells, or cellular fragments in the
sera of the healthy children. Consequently, the anti-𝛽2GP1
complexes can be cleared more efficiently by the powerful
complement system of the healthy children. In patients with
chronic inflammatory autoimmune diseases, complement is
usually low, which may result from null alleles [44] or from
complement consumption [38].
But why do these processes not cause inflammation and
aberrant coagulation in the children?Apart fromanti-𝛽2GP1-
IgG subclass distribution and distinct ability to activate the
complement system, it is likely that other properties of the
anti-𝛽2GP1 in the sera of children contribute to their low
pathogenicity. We hypothesized that an increased sialylation
of the anti-𝛽2GP1-IgG in healthy individuals renders them
harmless for their hosts. IgG is usually N-glycosylated at the
CH2-domain of its Fc-part. This N-glycan crucially modifies
the effector functions the IgG molecule is endowed with
[45–47]. This biantennary, core-fucosylated oligosaccharide
carries a variable amount of sugar monomers attached to
both arms [28, 48]. IgG antibodies terminating with sialic
acids on one or both antennae have been shown to behave
anti-inflammatorily after infusion of IVIG [29, 31].The signal
exerted by the terminal sialic acid is dominant since the
fraction of sialylated IgG in healthy plasma is just 4 to 14%
[28, 46, 49].
In mice, these effects are mainly ascribed to decreased
binding of sialylated IgG to activating Fc𝛾-receptors and
an upregulation of the inhibitory Fc𝛾RIIB [29, 31]. We
observed that anti-𝛽2GP1-IgG isolated from sera of healthy
children was significantly more sialylated than that from
symptomatic patients with APS. One may predict that these
autoantibodies, in complex with 𝛽2GP1, show low affinity for
activating Fc𝛾Rs and, therefore, do not provoke proinflam-
matory and procoagulant effector functions. Fc𝛾RIIA is an
example for an activating receptor. It is located on a plethora
of cells. On the surfaces of platelets, it mediates activation
by immune complexes. The activation is accompanied by
platelet aggregation and the release of mediators such as
the prothromboticThromboxaneA2 [50]. Consecutively, this
cascade can result in thrombus formation [51, 52]. Sialylated
anti-𝛽2GP1-IgG is unable to bind to and to activate platelets
via Fc𝛾RIIA.
Further mechanisms involved in thrombus formation in
APS comprise the interaction of anti-𝛽2GP1 with various
pattern recognition receptors [53] and its interference with
regulatory functions ofmolecules involved in the coagulation
process (protein C, prothrombin, or tissue factor [52, 54]).
Direct binding to 𝛽2GP1 on endothelial cells (EC) shifts
their phenotype towards coagulation and inflammation [54].
Considering that Fc𝛾R-binding is involved in many of these
mechanisms, it seems likely that a high sialylation of anti-
𝛽2GP1-IgG leads to a low pathogenicity of these autoan-
tibodies and does not cause APS. Therefore, we conclude
that the higher sialylation of anti-𝛽2GP1-IgG in the sera
of the healthy children plays a major role in protecting
them from typical complications of APS. This hypothesis is
further supported by the observation that antiphospholipid
antibodies from sera of asymptomatic adult carriers are
more sialylated than those from patients with APS. A high
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sialylation status of antiphospholipid antibodies seems to
prevent the development of symptoms of APS also in these
individuals.
We conclude that a plethora of factors contributes to
the low pathogenicity of anti-𝛽2GP1-IgG in the sera of
healthy children and asymptomatic adults. We observed a
distinct spectrum of IgG-subclasses compared to patients
with APS and a better binding of C3c indicating a more
efficient clearance of potentially harmful anti-𝛽2GP1. The
hypersialylation of the anti-𝛽2GP1-IgG is prone to ameliorate
their inflammatory and procoagulatory effects in healthy
carriers, whereas hyposialylation and inflammationmutually
precipitate the antiphospholipid syndrome.
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